TEMECULA, Calif., Sept. 23 /PRNewswire/ -- SurgiCount Medical, the wholly-owned operating subsidiary of Patient Safety Technologies, Inc. (OTC Bulletin Board: PSTX), announced that results of independent, unsponsored clinical research conducted by the Mayo Clinic on their multi-year effort to reduce retained foreign objects will be presented and discussed at two upcoming conferences. The research and related discussion will include the evaluation of the SurgiCount Safety-Sponge® System and its impact on retained surgical sponges at the Mayo Clinic.
The upcoming conferences are as follows:
23rd Annual Managing Today's OR Suite Conference, Orlando, Florida
Friday, October 1st, 9:30am – 10:45am
What Does It Take to Prevent Retained Foreign Objects
Robert R. Cima, MD, MA
Vice Chairman, Department of Surgery; Associate Professor of Surgery, Mayo Clinic,
Cheryl Weisbrod, RN, MSN
Nurse Administrator, Mayo Clinic
Sarah R. Pool, RN, MSN
Resource Nurse Manager, Mayo Clinic, Instructor in Nursing, College of Medicine
James D. Clark, RN, MSN
Nursing Education Specialist, Surgical Services, Mayo Clinic American College of Surgeons 96th Annual Clinical Congress, Washington DC
Tuesday, October 5th, 2:30pm – 4:00pm
Quality and Outcomes Session I
Robert R. Cima, MD, MA of the Mayo Clinic will present the clinical research study
"Evaluation and Implementation of a Bar Coded Sponge Counter System:
Impact on Retained Sponges After One Year" as part of a discussion panel
"We are honored to have our Safety-Sponge® solution validated by extensive, independent research conducted by such a prestigious institution and group of individuals. To my knowledge this is the first and only completely unsponsored clinical research on any technology solution to prevent retained surgical sponges. We will continue to follow the lead of the Mayo Clinic and other institutions to work to eliminate retained surgical sponges, a common yet entirely preventable surgical error," stated Brian E. Stewart, President and CEO of Patient Safety Technologies, Inc.
About Patient Safety Technologies, Inc. and SurgiCount MedicalPatient Safety Technologies, Inc., through its wholly-owned operating subsidiary SurgiCount Medical, Inc. provides the Safety-Sponge® System, a solution proven to improve patient safety and reduce healthcare costs by preventing one of the most common errors in surgery, retained foreign objects. For more information, contact SurgiCount Medical, Inc. at (951) 587-6201 or visit www.surgicountmedical.com.
Some statements in this release may be "forward-looking statements" for the purposes of the Private Securities Litigation Reform Act of 1995. In some cases forward-looking statements can be identified by words such as "believe," "expect," "anticipate," "plan," "potential," "continue" or similar expressions. Such forward-looking statements include risks and uncertainties, and there are important factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These factors, risks and uncertainties are discussed in Patient Safety Technologies, Inc. Annual Report on Form 10-K for the year ended December 31, 2009, as updated from time to time in our filings with the Securities and Exchange Commission.
Related medicine technology :1
|SOURCE Patient Safety Technologies, Inc.|
Copyright©2010 PR Newswire.
All rights reserved
. For Multiple Myeloma Treatment, More Surveyed European Clinicians Consider the Combination of Immunomodulatory Agents and Proteasome Inhibitors Promising With Respect to Efficacy Than Any Other Drug Regimen Combinations2
. Clinical Trial Establishes Catheter-Based Aortic Valve Replacement as New Standard of Care for Patients Who Cannot Undergo Surgery3
. Abbotts Fully Bioresorbable Vascular Scaffold Technology Continues to Demonstrate Strong Clinical Results4
. Wolters Kluwer Health and the Joanna Briggs Institute Enter Exclusive Relationship to Deliver Evidence-Based Clinical Resources5
. Boston Scientific Announces Clinical Data Supporting Safety and Efficacy of Platinum Chromium PROMUS Element™ Stent6
. OmniComm Systems, Inc. Hosts Autumn 2010 eClinical Forum Meeting7
. Almacs Clinical Technologies Division Undergoes Successful Joint GCP-GMP MHRA Inspection8
. immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio9
. ChemoCentryx Reports Positive Results and Completion of Phase I Clinical Studies of Novel CCR2 Antagonist, CCX140, at the European Association for the Study of Diabetes (EASD)10
. Kmart Pharmacy Announces Availability of Flu Shots at Walk-In Flu Clinics11
. PAREXEL Announces Strategic Functional Service Provider Relationship with Eli Lilly and Company for Clinical Development in Asia/Pacific Region